Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report released on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald boosted their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an overweight rating in a research report on Thursday, August 1st.

Vanda Pharmaceuticals Price Performance

Shares of VNDA opened at $5.08 on Friday. The firm has a market capitalization of $295.65 million, a PE ratio of -63.50 and a beta of 0.77. Vanda Pharmaceuticals has a 1-year low of $3.30 and a 1-year high of $6.75. The company’s fifty day moving average price is $5.48 and its 200-day moving average price is $5.11.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. The company had revenue of $50.47 million for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. As a group, research analysts anticipate that Vanda Pharmaceuticals will post -0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Meeder Asset Management Inc. acquired a new position in shares of Vanda Pharmaceuticals in the second quarter worth about $39,000. SageView Advisory Group LLC acquired a new position in shares of Vanda Pharmaceuticals in the first quarter worth about $34,000. SG Americas Securities LLC acquired a new position in shares of Vanda Pharmaceuticals in the second quarter worth about $61,000. China Universal Asset Management Co. Ltd. raised its position in shares of Vanda Pharmaceuticals by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 4,387 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth about $75,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.